Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Dupixent“
Suchtreffer
Begriffe & Kennungen
Dupixent · 4.8 · Adolescents (12 to 17 years of age)
Eintrag öffnenDupixent · 4.8 · Adolescents (12 to 17 years of age)
Eintrag öffnenDupixent · 4.8 · Adolescents (12 to 17 years of age) A total of 107 adolescents aged 12 to 17 years with asthma were enrolled i
Eintrag öffnenDupixent · 4.8 · Adolescents (12 to 17 years of age) The safety of dupilumab was assessed in a study of 250 patients 12 to 17 y
Eintrag öffnenDupixent · 4.8 · Antidrug Antibodies (ADA) responses were not generally associated with impact on dupilumab exposure, safety, o
Eintrag öffnenDupixent · 4.8 · Antidrug Antibodies (ADA) responses were not generally associated with impact on dupilumab exposure, safety, o
Eintrag öffnenDupixent · 4.8 · Approximately 1% of patients 1 year of age and older with EoE who received dupilumab 300 mg QW (≥40 kg), 300 m
Eintrag öffnenDupixent · 4.8 · Approximately 1% of patients 1 year of age and older with EoE who received dupilumab 300 mg QW (≥40 kg), 300 m
Eintrag öffnenDupixent · 4.8 · Approximately 16 % of adolescent patients with atopic dermatitis who received dupilumab 300 mg or 200 mg Q2W f
Eintrag öffnenDupixent · 4.8 · Approximately 16 % of adolescent patients with atopic dermatitis who received dupilumab 300 mg or 200 mg Q2W f
Eintrag öffnenDupixent · 4.8 · Approximately 4.7% of adult patients with CSU who received dupilumab 300 mg Q2W and adolescent patients with C
Eintrag öffnenDupixent · 4.8 · Approximately 5 % of patients with atopic dermatitis, asthma, or CRSwNP who received dupilumab 300 mg Q2W for
Eintrag öffnenDupixent · 4.8 · Approximately 5 % of patients with atopic dermatitis, asthma, or CRSwNP who received dupilumab 300 mg Q2W for
Eintrag öffnenDupixent · 4.8 · Approximately 8% of patients with COPD who received dupilumab 300 mg Q2W for 52 weeks developed antibodies to
Eintrag öffnenDupixent · 4.8 · Approximately 8% of patients with COPD who received dupilumab 300 mg Q2W for 52 weeks developed antibodies to
Eintrag öffnenDupixent · 4.8 · Approximately 9 % of patients with asthma who received dupilumab 200 mg Q2W for 52 weeks developed antibodies
Eintrag öffnenDupixent · 4.8 · Approximately 9 % of patients with asthma who received dupilumab 200 mg Q2W for 52 weeks developed antibodies
Eintrag öffnenDupixent · 4.8 · Atopic Hand and Foot Dermatitis The safety of dupilumab was assessed in 27 paediatric patients 12 to 17 years
Eintrag öffnenDupixent · 4.8 · Atopic Hand and Foot Dermatitis The safety of dupilumab was assessed in 27 paediatric patients 12 to 17 years
Eintrag öffnenDupixent · 4.8 · Atopic dermatitis
Eintrag öffnen